OoDJsigTr Ersvelopa ID.. 305A8W&4D4-8AE44122.F680CIPAE87A Registered number: 11943477 Charlty numbei: 1185091 FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) AUDITED TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 AFBKF6sr 2PJ09r2026 CCWPAWIES HOUSE A18
57
Dor#JstyJn EnveloFe10.. 30&48&4&8AD4-&4E4-8122.F680C1A8EB7A FOLUCULAR LYMPHOMA FOUNDATION (A company limited by guarantee CONTENTS Page Reforence and administrative d•tails of the Company. ils Trustees and advIr$ Trustees. report 2-13 Independent audltorfs repwt on the financlal statements 14-17 Statement of financial activities Balance sheet 19 Statement of cash flows 20 Not•s to th• financlal statements
DcrJJsigTr Envelope10.. 30sA65&4D4-8AE4l228BDC1A8E87A FOLLICULAR LYMPHOMA FOUNDATION {A company Ilmlted by guarantee) REFERENCE AND ADMINISTRAnVE OAlLs OF THE COMPANY. ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEM8ER 2025 Trnstees Lady N S Menddsohn. Chair Lord J N Mendelsohn Lord R l Harrington P M V Thompson A Wong J J Burley Dr J W Simons Company register•d number 11943477 Charity registered number 1185091 Regislored office 417 Finchley Roaj London NW3 6HJ Chlef executlve officer E France (appointed 1st Febry 20251 Independent auditor Cooper Parry Group Limited Cubo Bimiingham 4th Fkx)r Two Chambertain Square Birmingham B3 3AX
Doojsign Énvaope ID.. 305A65AWW4-8122.FWC1A8E87A Folllcu . FOLUCULAR LYMPHOMA FOUNDATION TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2025 The Trustees, who are also the directors of the charity for Ihe purposes of the Companies Act 2006. present their report together the financial statements for the year ended 31 Decernber 2025. The financial stalemenls have been prepared in accordance with the Charities SORP (Statement of Recommended Practice). applicable to charities preparing their accounts in accordan with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland (FRS 102). effeclive 01 January 2019. Objectives and Activities Our mission is to help those with follicular lymphoma. a currently incurable blood cancer. to live well and get well by finding and funding the best research to identify breakthroughs that will change how we understand and Ireat the condition. We provide follicular lymphoma- focused information resources for patients and work to ensure palients, voices are at the heart of the search for better treatrnents and a cure. More s ecrficall the Chari 's ob"eclives are the followin A. To sponsor basic and translational Search to assist in the development of better treatments and a cure for follicular lymphoma induding sponsoring the establishment of an international challenge to scienttfic and Clinical researchets to focus on prospective cures. To support the promotion of the "patient Vol.. by supporting patient advocacy and education. the development of patient communtiies and evaluating the efficacy of patient-reported outcomes on current treatments and side effects to assist clinicians and pats'ents. C. To improve health outcomes by way of stimulating research and evaluation of complementsry condttions to supplement medical treatment. Publlc Benefit - The Trustees confirm that they have complied with their duty to have due regard to the Charity Comrnission's public benefit guidance when reviewing the charity's objectives, activities and future plans. The Trustees consider that the charity's activities provide public benefil by funding research into follicular lymphoma, supporting the development of better treatments and approaches to care, providing trusted infomiation and support for people affeded by follicular tymphoma. and ensuring pats'ent experTrence helps shape research, education and engagement priorities. Achievements and perfomiance 2025 was a year of focused progress for the Follicular Lymphoma Foundation (FLF). Scientrfic understanding advanced. new treatrnent approaches moved closer to patients. and expectations of what is possible continued to shtft. FLF tumed urgency into practical mornentum by funding research thal targets the biggest barriers to cure. engaging patients at scale and building the partnerships needed to move promising science further and faster. The Follicular Lymphoma Foundatron fo@Iheflf.019 ww.thelll.Or¥ +441012034178563 FR FUINDgAISINIG REGULATOR
Docustgn Envebpelo.. 30SA85eAOEd-8122-F6BDC1ME87A FOIII¢v hof In 2025, FLF invested in cure-focused research and patient programmes. supported artive translational research programmes addressing relapse, treatment resistance and treatment durabilily, captured patient experience through global survey responses and wider ommunity engagernent. and direded the majority of expenditure toward research and patient programmes. Tt)Jether, this shows a clear model in which donor support enables research, research creates pathways to palient benefiL and patient insight ensures progress is anchored in what matters most in real life. When I look at what has been achieved in 2025. 1 feel a powerful mix of pride and determination. Pride, because the progress is real. Detennination, because il is not yet enough. Every study. every data point and every collaborafyon is a step toward the future patients deserve.. one where follicular lymphoma is no longer a lrfe-defining diagnosis. Cure cannot wait. Neither carp we." Nicola Mendelsohn CBE. Founder and Chair. Follicular Lymphoma Foundation 2.1. Research programrnes The FLF'S research programmes are designed to tum promising science into better patient outcomes for people affected by follicular lymphoma. Each programme addresses an important unmet need, with the potential to improve treatment and move closer to cure. At the heart of every programme is a clear-so Wha.: what this could thange for patients. what new evidence it could generate for the field. and how FLF'S support helps improve Patnt outcomes sooner. 2.1.1. The CURE FL Awards The CURE FL (Curative Research to Eliminate Follicular Lymphoma) Awards were the first round of FLF'S CURE FL Programme. designed to answer one of ihe bKJgest questions in follicular lymphoma." why does the disease return after powerful immune-based treatments, and how can we stop it? This programme ran from Dernber 2022 to July 2025 in collaboration with the Milken Institute. deploying approximately $2 million across four translalional research projects. Each project received $500.000 over IAVO years. The focus was on transfomiative projects addressing relapse and treatment resIStsn after immunoiherapy. area5 FLF identified as having the greatest potential to generale eviden that could lead lo better therapies rea¢hing patients sooner. What it made possible The CURE FL Awards helped move promising scientific discoveries closer to the people who need them most. Across four Iranslational research projects, the programme generated new insights into treatment Sistance and relapse after immunotherapy, strengthened understanding of the biological mechanisms that drive relapse, and helped advance promising discoveries from the laboratory towards patient studies. The programme also generated evidence. collaborations and new scientific insights that exterm4 beyond follicular lymphoma. helping infom) research across the wider lymphoma field. The Follicular Lymphoma Foundalion Infr@Ihefll.Or9 wvrw.theflf ov9 +4410120341Y8SB3 FR FUiNiDR&ISING REGULATOR
Docusvjn ETrvdope ID.. 3054850At)4&1£&al2268Oc1A8EB7A Folll¢u . What we learned The CURE FL Awards showed that relapse after immunotherapy is not an immovablè barrier. The funded projects generated new insights into immune escape. treatmenl resistance and how treatment responses could become deeper and more durable. Two projects progressed to the final preclinical stages required before potential testing in patients. with one of these going on to inform two clinical studies. A third projecl mel its objectives by validating a potential new strategy to prevent relapse and generating the eviden needed to move that approach closer to patients. The fourth generated useful insights that continue to infomi the field, and FLF will Continue lo monitor future developments arising from this work. Why it matters Collectively, these outcomes demonstrate how translational research Can "advance understanding. infomi future studies and help bring cure doser for people living with follicular lymphoma. By answering critical questions about why treatment stops working and what drives relapse, the programme is helping identrfy new approaches that could lead to more durable responses and improved outcomes for people living with FL. The knowledge generated may also help infom research into related blood cancErs that share similar biological pathways. Read more 2.1.2. Research Unlted to CURE FL Awards Building on the first CURE FL Awards. Research United to CURE FL is the second round of FLF'S CURE FL Programme. Launched in 2024 in partnership with Blood Cancer United, formerly the Leukaemia & Lymphoma Society, and the Inslitute for Follicular Lymphoma Innovalion, the partners awarded $2.25 million to three promising follicular lymphoma research projects. What il focuses on Research United to CURE FL supports translational research designed to move scientific ideas closer to clinical trials and patient benefit. The funded projects focus on three areas with clear relevance to patients- understanding resistanc8 to immune-based treatments, developing more WeSe targeted therapies. and testing a chemotherapy-free firsl-line treatment approach. Why it matters As Ireatment options grow. the challenge is not only finding new therapies but knowing how to use them better. Patienls need treatment approaches that are more precise. less toxic, and more likely to deliver deep, lasling responses. The biological queslions these projects address are also relevant beyond follicular lymphoma. with the potential to inform research into related blood cancers. 2025 progress In 2025, the Research United to CURE FL projects advanced novel targeted therapies, completed enrolment to a 35-patsent chemotherapy-free clinical trial with encouraging early results. and generaled new biological samples. data and research models to better understand why follicular lymphoma can persist or retum after treatment. Togelher, the projects delivered their first planned outputs and generated findings that will infomi the next phase of research. Read more The Follicular Lymphoma Foundation if*fhe 1lf.org 444{0120 3417 8583 FR FUNDR.4ISING REGULATOR
Dc¢)Jsgn Envebpe10.. 305A85A&8AD4-&AE44122.F6BDC1P4E87A Folllcu . 2.1.3. Tho FL Biomarker Discovery Programm• Launched in 2024 with projects activated in March 2025, FLF partnered with The Mark Foundation for Cancer Research on the FL Biomarker Discovery Programme. This partnership supports research to identify biological markers that could help predicl how follicular lymphoma behaves and how patients may respond to treatment. Over time, biomarkers could help support new treatment approaches and potentially preventative strategies. The programrne was developed with scientific. clinical and patient input. It focuses on key moments in higher-risk disease. including transformation, eady relapse and the early biological changes that can lead to follicular lymphoma. What It focuses on A biomarker is a biological signal, such as a molecule. protein. or gene. that can help predict what is happening in Ihe body and what may happen next. Reliable biomarkers for follicular lymphoma do not currently exist. This programme supports research using advanced technologies to better understand follicular lymphoma tumours. the irnmune cells around them, and the patterns that may be linked to relapse. transformatTron. or treatment response. Why it matters Biomarkers could mean clearer answers at moments of uncertainty.. who may need treatment straight away. who may be at hNJher risk of relapse or transformation. and which treatmenl approach may be most appropriate. For patients and clinicians. this could support more personalised decisions, reduce unnecessary treatment and enable earlier action when needed. 2025 progress In 2025, the selected projects were awarded, supporting research at The University of Texas MD Anderson Cancer Center and Yale School of Medicine. The two-year funded projects use advanced spatial technologies to study follicular lymphoma tumours and their surrounding immune environmenl. Tcoether, they aim to identify pattems that could predict prognosis, progression, transformation. and response to treatment. Read more 2.1.4. PETReA Plus Programme PETReA Plus is a UK-based observational study generating critical data from people noY diagnosed with follicular lymphoma. Led by Professor Kim Linton al The Universiiy of Manchester. the programme runs from Seplember 2024 to September 2029 and is funded in partnership with Blood Cancer UK and The joy and Nomian Freed Charitable Trust. The sludy is designed to help clinicians and patients make more informed. personalised decisions about treatment in the future. It is contributing to what is expected to become one of the largest global resources of follicular lymphoma data and patient samples. creating a resource that could support future research well beyond this individual study. What It focuses on PETReA Plus is collecting outcomes from the initial management of people newly diagnosed with follicular lymphoma. It sits alongside PETReA, an intemational trial focused on understanding the best use of rituximab according to dsfferent risk groups. The Follicular Lymphoma Foundalion info@Ihe 111.org WWw.Ihellf.or9 +44101203417 8583 FR FUIIDWISINIG REGULAfoR
OrLus¢gn Envtbpe ID.. 305A8SA&8A44122-F6B1I4E87A Foiiicu hof Why It matters As treatment options grow. one of the most important questions is how to use them well. PETReA Plus will help address knowledge gaps that cannot be answered through current clinical Irials alone. By capturing evidence from routine care, the study could help link different diagnoses and treatment approaches with different outcome5. SUPPOrting more personalised care. better-informed decisions and fewer unnecessary toxic trealments. 2025 progress With a target of r8cruiling 500 patients from 65 sites in the UK, the PETReA Plus study team made consistent progress in 2025 towards preparing for rewitment. By December 2025. the first patient had been recruited to the study. "The real detenninant of whether a study sinks or swims is how popular it is with local sites - how many sites want.to nin the study and how enthusi8Stic they are about recniiting patients. I see the whole spectrum across my area of clinical research, and I have to say this on8 IS flying, now the sites are starting lo open." Dr An(ty Pettttt. co-investigator on the PETReA Plus study Read more 2.2. People affected by folllcular lymphoma at the heart of our work The FLF supports people today while leaming from lived experience to shape tomom)w. People affected by follicular lymphoma help inform the charity's research. patient information and future programmes through suNeys. discussion sessions and patient representatives, ensuring the work remains grounded in the outcomes that matter most in real life. 2.2.1. Patient support and education Living with follicular lymphoma raises questions about diagnosis. trealment. uncertainty and where lo find reliable support. FLF provides accessible, expert-informed informalion based on up-t&date evidence. along wth opportunities to hear from experts and others affected by the disease. In 2025, 14.438 people used Your Su ort Hub on the FLF website for trusted infomiation and support. 22.765 webinar views connecled patients and caregivers with expert insight and lived experience, and 123,000 views of patient stortes helped peoplè feel less alone and more informed. This support has immediate practs'cal value.. people are better equipped to understand follicular tymphoma, prepare for conversats'ons with their healthcare teams and make informed decisions about their care. It also helps people feel less alone and more connected to a community that understands what they are facing. Over time. better infomation also supports the FLF'S wider mission. When people understand research, dinical studies and the role of patient participation. they are better placed to engage with opportunities that can help develop new treatments and move the field doser to cure. "I very much appreciate everything that this team puts together to keep your global audience and patients 'in the kno and w811 infonn8d. I think you do an absolutely amazing job on such a large scale." Anonymous restK)nse to the FLF patient survey The Follicular Lymphoma Foundation nlo@thelll.org v4ww.theiif.org +441012034178583 FR FUINDPAS1NG REGULATOR
Docusign Envekye ID.. 3O5A85A8.8AD444E4-8l226BDClEe7A Folllcu 2.2.2. The patient voice People affected by follicular lymphoma help shape FLF'S research. patient infomation and future programmes through surveys. discussion sessions and patient representatives. Patient insight ensures FLF focjjses not only on what is scientifically possible. but also on the outcomes thal matter most to people Irving with follicular lymphoma, from reducing uncertainty and improving communication to supporting informed treatment decisions. In 2025, patient insight helped inform research strategy, global patient suNey content and interpretation, scientific education for healthcare professionals. and events and parlnerships focused on improving patient outcomes. This brings FLF doser to cure by grounding scientific priorities in real patient experience, so research focuses on what could make the greatest difference in people's lives. 35 highly engaged palient contributors helped shape FLF'S research and patient information, 1,042 responses were received through FLF'S global patient survey, and more than 100 countries were represented through community engagement and wider networks. An example af patient insight in action Through the Global Patient SuNey and focus groups in 2025, people affected by follicular lymphoma helped shape FLF'S global patient survey through a face-to-face workshop. Through further online discussions. they also played a key role in interpreting the findings. Their insight highlighled the real-life importance of treatment preferences, uncertainty, communication and decision-making about dinical tn'als. The difference it made.. these insights were shared directly with researchers and healthcare professionals at forums such as the American Society of Haematology symposium and FLF investigator workshops. helping ensure research and care are shaped by patiènt priorities. By bringing the patient voice into global decision-making. this work supports more meaningfvl shad decision-making and.helps patients access the treatments that are rbght for them. .1 was actually quite anxious prior to the meeting but quickly felt it so worthwhile. Hearing the views of others living with FL and being heard was importanl. The opportunity to help is huge." Lived Experien Discussion Attendee 2.3. Mobilising funding and partnorshlps Cure for follicular lyrnphoma will not come frcyn one individual. one organisation, one discipline or one type of eXpe'Se acting alone. FLF brings together researchers, dinicians, data specialists. industry partners, philanthropic funders and people living with follicular lymphoma around shared priorities, so that funding, expertise and patient insht can work harder together. This helps ensure the mosl promising science reaches people faster and moves follicular lymphoma closer to cure. "Pn?gress depends" on collaboration. No single organisation can move the fld alone, but logelher we can proted momentum. align effort and keep patients at the centre.. Emma France, Global CEO. The FLF The Follicular Lymphoma Foundation inlo@the ri1.9 W¥yw.thellf.org 444101203417 8583 FR FUNDRAISING REGULATOR
Do¢usign Érv¢l¢¥e .. 3o&A8YA4AD¥4-8l22468Oc}ABEB7A Folllcu . 2.3.1. What partnership made posslble in 2025 Larger, more ambitious research programmes Strategic partnerships enabled FLF to pool expertise and funding around larger. more ambitious research programmes. including Research United to CURE FL. the FL Biomarker Discovery Programme and PETReA Plus. A stronger bridge across fields FLF connected expertise from lymphoma research. immunology, clinical care. drug developfflent. philanthropy and patient experience, so promising work was shaped by more than one field from the start. Trusted patient education and Inslght FLF delivered palient education. preference research. webinars and healthcare professional engagemen( keeping patient need at the centre. A shared case for collal)oration FLF co-authored an article wth the Institute for Follicular Lymphoma Innovation and Blood Cancer Unf(ed on the Importan of collat)ration in accelerating progSS for people living with follicular lymphorna. 2.3.2. Key global partners In 2025 included: The Mark Foundation for Cancer Research - SuprM)rting hh-lrnpact cancer research that aClerateS breakthroughs in how cancer is understocrfl and treated. Co-funded the FL Biomarker Discovery Programme. Mllken Institute Center for Strategic Philanthropy COllatrating with the FLF to Strengthen strategic philanthropy. accelerate research and advanc8 patient-focused innovation. The Institute for Follicular Lymphoma Innovation - Advancing research and innovation lo support the devdopment of more targeted therapies for follicular lymphoma. Blood Cancer United - Working wtth the FLF to fund innovative follicukir lymphoma research through the Research United to CURE FL Awards and other shared initiatives. Bl¢)od Cancer UK - Partnering with the FLF to deepen understsnding of follicular lymphoma and support progress toward more tailored therapies. DKMS Supporting the FLF'S cure-focused research into new treatment approaches and technologies that could help improve outcomes for people living with folliGular lymphoma. Patlenl Group Partnerships - Working closely wtth global online communities that provide safe spaces, shared experience and SUPF)Ort for thousands of people affeded by follicular lymphoma. This includes the Livin wtlh FL FacebcM)k rou and Linfoma folicular= Comunidad Internacional de Pacientes Familiares The Follicular Lymphoma Foundation 1nloéllhelll.ors www.thÈlll.Or9 •441012034178583 FR FUINDQ.4151NG REGULATOR
Oocu8ign Enveknpe ID.. 305A85A8-8AD4-8AE4-8122.F6BDClhSE87A Folllcu hor Working across the wider field Alongside our Search and funding partnerships. the FLF works with clinicians, industry partners, healthcare educators and scientific communities where there is clear alignment wilh our mission and direct value for pats"ents. The FLF'S independence remains ntral. We work with partners to strengthen patient voice, improve understanding and suppcrt better outcomes. while keeping patient need and cure-focused progress at the centre. Plans for future periods 2025 showed what focused funding. patient insight and scientific collaboration can make possible. while reinforcing the challenge ahead= as research advances. progress must stay focused on the oulcomes that matter most lo people living with follicular lymphoma. In the next phase, FLF is focused on tuming this progress into stronger evidence. better- infomied decisions, deeper patient involvement. more aligned funding, clearer pathways from discovery to patient benefit, and insights that can inform research beyond follicular lymphoma. What we are focused ¢)n next Moving cure-focused Scien closer to patients. Building on our CURE FL portfolio to support research to understand what drives follicular lymphoma, identify people at greater risk, tackle relapse and treatment resistance. and improve treatmenl a roaches. Accelerating the development of new treatment approaches. Collaborating with partners to advance precision medicine-guided dinical trials and accelerate approval of innovatNe treatments for relapsed follicular lymphoma. What ress looks like Stronger evidence. clearer nexl steps and, where appropriate. the potential to inform future clinical studies. Approval and availability of treatments with breakthrough designation (wh8n regulators recognise potential to significantly improve palient outcomes) for relapsed follicular lymphoma. bringing newo tions to atients sooner. Better tools and evidence to support more infomied treatment decision5. reduce unnecessary treatment and side effects, and improve outcomes for different groups of patients. Making treatment more personalized. Advanang biomarker research, PETReA Plus and other dat&driven work lo better understand who may need treatment, when, which treatment may be most appropriate and how care can be better tailored to each erson. Ensuring patient insight shapes what comes next. Using surveys, discussion sessions. patient meet-ups and patient contn"butors to understand what matters most in real life. including treatment preferences. uncertainty, communication and clinical trial decisions. Building partnerships that accelerate progress. Working with researchers. clinicians. nonprofrt organizations. funders. industy partners and patient communities lo pool resources, share ex ertise and reduce du lication. Research priorities, educational resou$, partnerships and measures of success that continue to be clearly grounded in the needs and experiences of people living Wlth follicular lymphoma. More aligned funding. shared learning and faster movement from scienlific discovery toward patient benefit. Together, these areas will guide FLF'S continued work to lum promising science into better answers, better treatment decisions. longer-lasting responses and, ultimately. cure, while generating knowledge that can benefit research far beyond follicular lymphoma. The Follicular Lymphoma Foundation inlo@thpfll.ory WW.ihefif.or9 441012034178583 FR FUllDls1NG RÉGULATOR
Do¢uggn Envelo 10. 3ow5A&8A44l22.F6BDC1Ee7A Folllcu . Financial Review 4.1. Financial Position The financial stalemenls for the year ended 31 December 2025 show a surplus of £47.078. This positive result reflects the ojnts'nued support of our donors and partners, together with prudent financial management throughout the year. The charity remains in a strong financial position, providing a solid foundation from whith to expand its activities and further advance its charitable objectives in the years ahead. 4,2. Reserves Policy As of 31 December 2025. th8 charitys totsl funds and reseNes amounted to £1.286,694. The charity operates with a lean cost structure and rArefully manages its resources to maximise the funds available for charttable activities. The Trustees have established a reserves policy designed to ensure the charity maintains sufficient financial stability to manage operational risks and meet its ongoing commitments. The Trustees have determined that free reseprfes should be maintained at a level equivalent to approximately Ihree mnths of planned expenditure. This level is considered appropriate in light of the charity's operating model. committed expenditure. fundraising profile and ability to fflanage costs and commitments through regular forecasting and Board oversighl. The Trustees will continue to monitor free reserves throughout the year against the approved budget and forecast cash requirements. In addition to maintaining the formal reserves policy. the Trustees will seek to strengthen the charity's broader financia! resilien over tirne by diverstying income, managing expenditure carefully and building the funds available lo support fulure growth and long-term sustainabilily. 4.3. Going Concem The Trustees have assessed the chariws financial position. fulure plans and cash flow forecasts and are satisfied Ihat bt remains appropriale lo prepare the financial ststements on a going concern bas1S. This assessment is supported by an approved business plan and budget covering thè period to Dernber 2027. The charity undertakes regular financial planning and fflonitoring. including the preparation of updated forecasts throughout the year. enabling expenditure and resource requirements to be reviewed in detail while maintsining a long-term strategic focus. The Trustees continue to explore opportunities to strengthen the charity's long-term financial sustsinability and diversify income streams. This supports the fomial reserves policy by increasing financial flexibility and resilience. while ensuring that resources maIn available to deliver the charity's approved plans and charitable objectives. The charty has also o)ntinued to strengthen its organisattonal structure and operational capacity, demonstrating its commitinent to delivering its charitable objectives over the long tem. Having considered the charity's financial resources. forecast income and expenditure, and future plans, the Trustees have a reasonable expectation that the charity has adequale resources to continue operaling fof the foreseeable future. Accordingly, they Gonsider the going concem basis of accounting to be appropriate in preparing these financial statements. The Follicular Lymphoma Foundation inlo@thelll.org WYiw.Ihellf.oig +441012034178583 FR FUINDRAISING REGULATOR
Docusign Envelopa ID.. 305A85A8-8ADMAE44122-F6Btt1A8E87A hof 4.4. Prfnclpal Risks and Uncertalntles The Trustees are responsible for idents'fying, assessing and managing the principal risks facing the charity and for ensuring that appropriate systems and controls are in place. During Ihe year, the Trustees reviewed the charity's risk profile, with particular focus on the risks most relevant to FLF'S scale. intemational activities. research funding model and reliance on donor support. The principal risks considered by the Trustees include: income volatilty and concentration risk. given the importance of major donors and philanthropic partnerships- research delivery risk. including the need to ensure grants are awarded. monitored and evaluated effectively,. regulatory and Cornplian risk across the charity's UK and international operating context: data protection and infomation governance risk. particularly where patient engagement, surveys and digilal communications are involved- people and capacity risk as the organisation grows- and reputational risk arising from the charity's public profile, partnerships and patient- facing adivities. These risks are managed through Board oversight. regular financial reporting and forecasting, grant govemance and milestone review, due diligence on partners and funded activities, appropriate policies and procedures. data protedion controls. Insuran cover and ongoing review of organisational capacity- The Trustees also seek extemal professional advice where required, including in relation to legal. regulatory. employment and financial matters. The Trustees are satisfied that appropriate policies. procedures and c¢trOlS are in place to reduce the charity's principal risks to an acceptable level and to provide reasonable assurance against fraud, error and non-compliance. As FLF'S activities, partnerships and international reach Continue lo develop. the Trustees will keep the risk management framework under review and strengthen it where needed. 4.5. Structure, governance and management The Follicular Lymphoma Foundation {"FLF") is a charilabl8 company, incorporat8d in England and Wales and registered with both the Charity Commission for England and Wales and Companies House. The charitable company was incorporated on 12 April 2019 and is govemed by its Memorandum and Articles of Association. whh set out Ihe charity's objects, powers and govemance arrangements. FLF was registered as a charity with the Charity Commission on 29 August 2019. The Trustees, who are also the directors of the charitable company for the purposes of company law, are responsible for the overall governance and strategic direction of the charity and for ensuring Ihat it pursues its charitable objectives in accordance with its governing documents and applicable legislation. The Follicular Lymphoma Foundation operates through three separate legal entities, each estsblished arKI regulated within its respective jurisdiction.. The Follicular Lymphoma Foundation {FLF UK) a charitable company incorporated in England and Wales and registered with Ihe Charity Commission for England and Wales and Companies House. The Follicular Lymphoma Foundation US Inc. (FLF US) - a regislered 501{cl(3) charitable organisation in the United Statss with Employer Identification Number {EIN> 84-2338899. The Follicular Lymphoma Foundat40n iDIthe111.0rg www_thplTI.Org +441012034178583 Awktrèdwith FR FJINDQAISING REGULATOR
DO$)n Enwdope ID.. 30W5A8-8AD44AE48122-F68DC1A8E87A Folllcu . ho( The Follicular Lymphoma Foundation (FLF) Israel Ltd. {FLF Israel) an Israeli registered charity recognised under Section 46 of the Israeli Income Tax Ordinance. with company registration number 516798477. Each organisation is a separate legal entty with its own goveming board, statutory obligations and independent audit. While legally distinct. the three charities operate in close collaboration to deliver the Foundation's global mission. Many research. fundraising and operational programmes are undertaken joinlly across the entities to maximise impact and ensure coordinated delivery. FLF UK provides central operational and administrative support to FLF US and FLF Israel, including finance, govemance and other shared servIs. The costs of these services are recharged to the respective entities in accordance with agreed arrangements and are subject to approval by each entity's Board of Directors or Trustees, as appropriate. 4.5.1. Decision Making The Board of Truste8s meets fomially at least four times each year and is responsible for setting the strategic diredion of the charty, establishing key policies, and overseeing the effective delivery of its charitable objectives. The Trustees monitor the charitrfs performance. financial position. risk management framework and the impact of r(s activities, ensuring that resources are used effectively and in furtherance of the charity's mission. The Board comprises individuals with a diverse range of professional skills, expertise and experience relevant to the tharity's a¢b'vities. including govemance. finance. fundraising. research. healthcare. business and communications. This breadth of knowledge supports robust decision-making and effective oversight of the tharity's operations and long-term development. 4.5.2. Statement of Trustees. Responslbilities The Trustees {who are also the directors of the Follicular Lymphoma Foundation for the purposes of company law) are responsible for preparing the Rep)ort of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally ACpIed Accounting Practice) including Financial Reporting Standard 102"The Financial Reporting Standard applicable in the UK and Republic of Ireland. Company law requires the Trustees to prèpare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources. including the income and expenditure, of the charitable company for that period. In preparing those financial statements. the Trustees are required to: select suitable accounting pdicies and then appty them consistently observe the fflethods and principles in the Charity SORP make judgements and estimales that are reasonable and prudent state whether applicable accounting standards have been followed, subject to any malerial departures disdosed and explained in the financial ststements prepare the financial ststements on a going concem basis unless it is inappropriate to presume that the charitable company will continue in business The Follicular Lymphoma Foundation info@iheflf.019 ww.thefll.org +44 IOIZ034178583 FR FUINDPAISING REGULATOR
D[S19Th Envekye ID.. 3o5A85A8-8AE4-8I22.F680cIlIEa7A hor The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial posib'on of the charitable company and to enable them to ensure thal the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and deleclion of fraud and other irregularities. So far as the Trustees are aware: there is no relevant audit information of which the charitable company s auditors are unawara" and the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that infomation. Auditors The auditors. Cooper Parry Group Limited, NMII be proposed for re-appointment at the forthcoming Annual General Meeling. Report of the Trustees. incorporating a strategic report, approved by order of the board of Trus188s, as the company directors. on 25 September 2026 and signed on the board's behalf by: by: DAfj2894W78..:................ Lord J N Mendelsohn - Trust8e The Folli¢ular Lymphoma Foundation info@Iheflf.ov9 www.thefll.ory 44410120 34178583 FR FUiqDRAISINIG REGULATOR
Docu5vJn ErweI0 ID". WwSA&8AuI22-F6BDelABE87A FOLLICULAR LYMPHOMA FOUNDATION (A company limiled by guarantee} INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION Oplnlon We have audited the financial slalements of Follicular Lymphoma Foundation (the 'charitable compan1} for the year ended 31 December 2025 which comprise the Statement of finanual activf(ies. the Balance sheet. the Slalement of cash flows and the related notes. including a summary of significant accounting policies. The financial retx)rb'ng framework that has been applied in their preparat is applicable law and United Kingdom Accounting Sland8rds. ClUdIng Financial Rep)rting Slandard 102 The Financial Reporting Standard applicable in the UK and Republie of Ireland. (United .gdoM Generally Accepted Accounting Practice). In our opinion the financial stalements: give a true and fair view of the state of the eharrtable companys affairs as at 31 December 2025 and of ils incoming resources and application of resources. including ils income and expenditure for the year then ended" have been properfy prepared in accordance with United lQngdom Generally Accepted Accounllng Practice-. and have been prepared in accordance wtth the requireffEnts of the Charities Act 2011. Basis for opinion We conduded our audit in aCCordare with Intemational StsrKlards on Audtting (UK} (ISA5 IUK)) and applicable law. Our respgnsibilities undef those standards are further described in the Audrtorfs responsibiltties for the audit of the financial 51alemenis section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom. including the Financi81 Reporting Counul's Ethical Standard. and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe Ihat the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern In auditing the financial ststements. we have concluded that the Trustees. use of going concern ba$1$ of accounting in the preparati of Ihe financk81 statements is appropriate. Based on the work we have perfomied. we have not identified any material uncertainties Lating to events or conditions that. individualty or colleclivdy, may cast signfficant doubt on the Charitable companys ability to continue as a going concem for a period of at least fvRlve months from when the financial statements are authorised for issue. Our TesFonsibilrties and the respbilitieS of the Truslees th respect to going eccern are described in the relevant sections of this reporL a4A
OooJ8igTr Envelop¢10". 305A85A8.8AD44AE4-8122-F68DC1NAE87A FOLLICULAR LYMPHOMA FOUNDATION (A company Ilmlted by guarantee) INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (CONTINUED) Other informatlon The other information comprises th8 information induded in the Annual report other than the financial statements and our Auditorfs report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and. except lo the extent olheThMse expl10Y staled in our rewrt. we do not express any fomi of assurance condusion thereon. Our responsibility is to read the other infomatyon and, in doing so. consider whether the other infomiation is materially inconsislenl with the financial stalements or our knowledge obtained in the course of the audit. or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent fflatellal rnisslatements. we are required to delemiine whether this gives rise to a material misslatemenl in the financial statements themselves. If. based on the work we have perfomied, we conclude Ihal there is a material misstslement of this other infomiabon, we are required to report that fact. We have nothing to report in this regard. Matters on whlch we are requlred to report by excepllon We have nothing lo report in respect of the following matters thre the Charities (Accounts and Reports) Regulations 21)08 requires us to report lo rf. in our opinion: the infom)alion given in the Tnjstees. rewrt is innSIStenI in any malerial respect with the financial slaternenls: or sufficient accounting records have not been kept.. Of the finanual stslements are not in agreemenl wilh the accounting records and returns.. or we have not received all the information and explanations we require for our audil. Responslbllltles of trustees As explained more fully in the Trustees. responsibilities statement. Ihe Trustees {who are also the directors of the charitable company for the purposes of company lawl are responsible for the preparation of the financial statements and for being satisfied that they gNe a true and fair view, and for such internal control as the Trustees delemiine is necessary lo enab Ihe preparation of financial ststements that are free from material misstatement, whether due lo fraud or error. In preparing the financial statements. the Trustees are responsible for assessing the chafitable CoMpanS ability lo continue as a going concem. disclosing. as applicable. matters related lo going concem and using the going concem basis of accounting unless the Trustees either intend to liquidate the charitsble company or to cease operations. or have no realistic alternative but to do so. nts14
D$19 Envelope10.. 3QS485AmAoE¥6l22.F680clE87A FOLUCULAR LYMPHOMA FOUNDATION IA company limited by guarantee) INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION (CONTINUED) Auditorfs responslbilities for the audll of Ihe Ilnanclal statements We have been appointed as auditor under sectTron 145 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effecl thereunder. Our objectives are to obtain reasonable assuranee atojl whether the financial statements as a whole are free from material misslalement. whether due to fraud or error. and to issue an Auditorts report that includes our opinion. Reasonable assurance is a high level of assurance. but is not a guarantee that an audit conducted ir¢ accordance with ISAS (UK) wll always detect a material rnisslatement when it exists. Misstatements can.anse from fraud or error and are considered material rf. indmdually or in the aggregate, they could reasonably be expected lo influence Ihe economic decisions of users laken on the basis of these financial 5tstements. Irregularities. including fraud. are instances of non-compliance with laws and regulations. We design procedures in line wth our responsibilitses. oulined above, to detect material misstatements in respect of irregularities. including fraud. The extent to which our prowlures are capable of delecling irregularities, induding fraud is detailed below: Our assessment focussed on key laws and regulations the charttable company has lo comply with and areas of the financial statements we assessed as being rnore susceptible to misstatement. These key laws and regulations included bul were not limited lo compliance with Ihe Companies Act 2006. Charities Acl 2011. Trustees Act 2000, Charities {Protection arKI Srxial Inveslment) Act 2016. taxation legislation, data proteelion and employment legislation. We are nol responsible for preverbting irregularities. including fraJ. Our approach to delecling irregularities. including fraud. included. but was not limited to. the following= obtaining an understanding of the legal and regulatory framework applieable to the charitable company and how the chaiilable ccmnpany is complwng with that framework. induding agreement ol financial statement disclosures to underfying documenlation and other eviden.. obtaining an understanding of the eharitsble companls control environmenl and lW Ihe eh8rilable company has applied relevant control procedures. through discussions th Trustees and other management and by perfoming walkthrough lesb.ng over key areas: obtsining an understanding of the charitsble companls risk assessment process, including the risk of fraud.. reviewng meeting minutes of those charged with govemance throughout the year, and perfomiing audit tesling lo address the risk of management override of controls. including testing joumal entries and other adjuslments for appropriateness. evaluating the business rationale of significant transactions oulside the normal course of business and reviewng accounting estimates for bias. Because of the inherent limttalirms of an audit. there ts a risk that we 11 not detect all irregularities, Including those leading lo a material misstaterr£nt in the financial stslements or non-compliance wth regulation. This risk increases the more thal compliance with a law or ulatiOn is removed from the events and transacts.ons reflected in the financial stalefflents. as we 11 be less like5y to become aware of instances of non-eompliance. The risk is also greater regarding irregularitS occurring due lo fraud rather than error. as fraud involves intentional coneealmenl. foigery. collu&on. omission or misrepresentation. A further description of our resFonsibilities for the audit of the finanrial statements is located on the Financial Reporting Coun1.S website at: www.frc.o -uklauditorsre5 nsibilitses. Thi5 description forms part of our Auditorfs report. •1R
D(xxJ$ign Env¢kty)o ID.. 305A85AD4-8AE44l22O8tClE87A FOLUCULAR LYMPHOPAA FOUNDATION (A company lirnited by guarantee) INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF FOLUCULAR LYMPHOPAA FOUNDATION (CONTINUED) Use of our report This reKM)rt is made solely to the charilable CompanYs members. as a bcKly. in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might stale lo the charitable Companys members those matters we are required 10 Stale to them in an Auditorfs report and for no other purpose. To the fullest extent permitted by law. we do not accept or assume responsibility lo anyone other than the charitable Company and its members. as a body, for our audr( woth, for this report, or for the opinions we have fomed. Nichola Hodge for and on behalf of Cooper Parry Group Limited Cubo Birmingham 4th Floor Two Chambertain Square Birmingham 83 3AX 4D52 enior ory Auditor 25 September 2026 CcK)per Parry Group Limited are digible to act as audtlors in terms of section 1212 of the Companies Act 2006.
DocusvJn Envdepe ID.. 305$84Da4E8122.F6BDC1A8E87A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT) FOR THE YEAR ENDED 31 DECEMBER 2025 Restricted Unrestri¢led funds funds 2025 2025 Totsl funds 2025 Totsl funds 2024 Note Income from: Oonalions and legacies Investments Other incoff 958.784 1.451.472 5.776 89.212 2.410.256 5.776 89.212 2.384,538 7,241 Total income 958.784 1.546.460 2.505.244 2,391.779 Expendlture on: Raising funds Charitable activities= Research and patient programmes Research and patient programme support costs 250,928 250,928 224,630 870.849 1.114.792 1.985.641 2,041.408 221,597 221,597 150,479 Total expenditure 870.849 1.587.317 2,458.166 2.416.517 Net in¢omel{expenditure) Transfers between funds 87.935 40.276 140.857) 140.276) 47.078 {24.738} 15 Net movement In funds 128.211 181.133) 47,078 124,738) Reconciliation of funds: Total funds brought for%Yard Nel movement in funds 137.074 128.211 1.102.542 181,133) 1.239.616 47,078 1,264,354 124.738} Total funds carried forward 265.285 1.021.409 1,286.694 1.239,616 Conllnuing oporations All income and expenditure has arisen from ctinUing activities.
Docusvjn Envek)pe ID.. 305A85A&8A04.8AE4-8122*6Btf1E87A FOLLICULAR LYMPHOMA FOUNDATION (A company Ilrnited by guarantee) REGISTERED NUMBER: 119434TI BALANCE SHEET AS AT 31 DECEMBER 2025 2025 2024 Note Flxed assets Tangible assets 12 9.074 7.381 9.074 7,381 Current assets Debtors 13 18 1.043.887 988.9C 212.674 1.805.674 Cash at bank and in hand 2.032.793 2.018.348 Current liabilities Creditors.. amounts falling due within one year 14 {755,173) {786.1131 Net current assets 1.277.620 1,232,235 Totsl net assets 1.286,694 1.239.616 Charity funds Restricted funds Unrestricted fuThJs ' 15 265.28S 1.021.409 137.074 1.102.542 15 Total funds 1,286.694 1,239.616 These financial statements have been prepared in aeeordance with the provisions applicable to eharitable companies subject to the small companie5 regirne. The financial statements were approved and authorised for issue by the Trustees atKI signed on their behalf by.. Lord J N Mendelsohn - Tnjstee Date.. 25 September 2026
OorJJsi9n Envelopa ID.. 305A85A4AE4122-F6BDc1AeS87A FOLLICULAR LYMPHOMA FOUNDATION . {A company Ilmited by guarantee) STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2025 2025 2024 Cash flows from opgrating activities Cash generated.from operations 1817.511) 515.458 Cash flows from Investing actlvltles: Purchase of tangible fixed assets Interest received 15.033) 5.776 14.397) 7.241 N•t cash lused in)Iprovid•d by investing activities 743 Change in $h and cash gquivalents in the y•ar Cash and cash equivalents at the beginning of the year (816.768) 1.805.674 518.302 1.287.372 Cash and cash equivalents at the end of the year 988.906 1,805.674
DOCUS¥ Enveknpe ID.. 305A8sA8-8A04Ee122.F61E87A FOLLICULAR LYMPHOMA FOUNDATION (A company limlled by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Accountlng pollcles 1.1 Basis of preparation of financlal staternents Follicular Lyfflphoma Foundation is a private eompany limited by guarantee, and is a registered charity incorporated in England and Wales under the Companies Act 2006. The charity is registered with the Charity Commission for England and Wales {Charity No.. 11850911. The finanual statements have been prepared in accordance with the Charities SORP IFRS 1021- Accounting and Reporting by Chaiities= Statement of Recomrnended Practice applicable lo charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland IFRS 1021 (effective 1 January 2019). the Financial Reporting Standard applicable in the UK and Republic of Ireland {FRS 102} and the Companies Ad 2006. The financial stslements have been prepared under the historical cost convention. The financial statements are presented in GBP {£). which is the presentational currency of the charity. The charity meets the definition of a public benefrt entsty under FRS 102. Assets and liabilities are inits.ally recognised at historical cost or transaction value unless otherwise slated in the relevant accounting policy. Individual fKJures are rePd in whole numbers, rounded lo the nearest £1. 12 Going concern The financial slalements have been prepared on a going concern basis. The Trustees have reviewed and considered relevant infomiation, including the annual budget and future cash flows in making their assessment. Based on these assessment5. and the current resources available. the Trustees have concluded that they can continue to adopt the goin9 concem basis in preparing the annual report and accounts. 1.3 Income All income is recognised once the Company has entitlement to the income. it is probable that the income will be received and the amount of income receivable be measured reliably. Oonations are recognised when the charity is enlilled to the income. receipt is probable and the amount can be measured reliably. Restricted donations are credited to the appropriate restricted fund. Donations subject to conditions that have not been met al the year4nd are d8ferred until those conditions are sabsfied. Gift Aid is rec(gnised when the related dOnatn is rer))gnised. Interest reeeivable is recognised HI the Ststemenl of Finanual Aclivities on an accruals basis as it is earned. 1A Donated goods. seTvlces and volunteers Donated goods. SeThI and facilities are recognised as income at fair value when receipt is probable and the value can be me85ured reliably. with an equivalent amount recognised as expenditure or as an asset as appropriate. The time given by volunteers is not recognised in the finawal stslements.. the role of volunteers is described in Ihe Trustees. report.
DoSign Envd*Jpe ID.. 30W5A&8AD44AE44122.F6BDC1A8E87A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 AccountSng policles Iconlinued) 1.5 Expenditure ExndItUre is recognised once there is a legal or constructive obligalion to transfer economic benefit to a third paty. rt is probable that a transfer of economic benefits will be requir8d in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by actwity. The costs of each activity are made up of Ihe lolal of direct costs and shared costs. induding support costs involved in undertaking each acb"vrty- Direct Costs attributable lo a single actiwty are allocated directly to that acb"vity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single acb.vity are apportioned beeen those activities on a basis consistent with the use ol resources. Central staff costs are allocated on the basts of b.me spent. ar depreciats.on tharges all¢)caled on the portion of the assays use. Expenditure on raisirvJ fvnds indudes all experKlIre incurred by the Company to raise funds for ils charitable purp)ses and includes costs of all fundraising activities events and non-charilable trading. Expenditure on charitsble activities 15 inojrred on direcuy undertaking the activities which further the C0rnpanS objecti've$. as well as any associated sUprM )sts. Costs of actNilies indude support costs and governance costs which have been allocated befv4e8n activities on the basis set out bekm. Support Costs Support costs are those lunctions that assist the work of the charity bul do not direclly undertake charitable aclivilies. Support costs indude central office functions such as finance. human resources. information technology and general management. These c0515 have been allocated beeen activities on the basis of staff time spent on each activity. whieh the Trustees consider lo be the most appropriate basis given the nature of the eosls incurred. Governance costs Governance costs indude costs of the preparab.on and examination of the ststulory accounts, the costs of trustee rneelings and the cost of any legal advice on govemance matters. 1.6 Grants and r•s¢arch funding Grants and Tesearch funding payaue in furtherance of the ¢hariWs objects are re¢ognised as expenditure, and a corresponding liability, once there is a legal or constructive obligation committing the charity to the payThent and the 8mount can be measured reliably. Where funding is conditional on future performance or events wthin the chanlls control. il is recognised only as those ¢ondibons are Ir1. 1.7 Taxatlon The Company is considered to pass the iests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it rneels the definition of a charitable company for UK corporation tax purposes. Aeeordingly. the Company is potentially exempl from tsxats'on in respect of income or capital gains received within cale9ories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992. to the extent that such income or gains ara applied excluswdy to charitable purposes. The charity 1$ not registered for VAT. Irreeoverable VAT is included wthin the cost of the expenditure or asset to whith it relates.
Docusw En¥e&)pe ID.. 3Q5A85A&8AD&IE4-8122.F6BOClPE67A FOLUCULAR LYMPHOIAA FOUNDATION IA company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Accounting policies (contlnued 1.8 Tan9ibl• flxed assets and depreclatlon Tangible fixed assets are initially recognised at cost. After recognition, under the cost model. tsngible fix9d assets are measured at cost less aCmUlated depreuation and any accumulated irnpairment 105ses. Al costs incurred lo bring a tangible fixed asset inlo its intended working condition should be included in the measurement of cost. Depciall0n is charged so as to allocate the cost of tangible fixed assets less their residual value over Iheir estimated usefvl lives. using the straighl-line method. Depreciation is Fwovided on the following basis: Computer eqvipment 33% 1.9 Currgn¢y The functional and presentation currency of the charity is pounds sleding {£). being the currency of the primary economic environment in vthich it operates. Transaclions 'in foreign currencies are translated at the rate ruling at the date of the transacbon. Monetary assets and liabilities denominated in foreign cuentles.al the balance sheet dale are retranslated al Ihe closing rate. All exchange gains and losses are recognised in the Slalement of Financial Activilies in the period in which they arise. The charity does 1 use f*dging instruments. 1.10 Debtors Trade and olher debtors are recognised at the settlement amounl after any trade discount offered. Prepayments are valued at the amounl prepaid nel of any trade discounts due. 1.11 Cash at bank and in hand Cash al bank and in hand indudes cash and short-term highly liquid investments with a short maturity of three months or less from the dale of acquisiknon or opening of the deposit or similar account. 1.12 Liabilftles and provlslons Liabilities are recognised when Ihere is an obligation at the Balance sheet dale as a result of a past evenL it is probable that a transfer of economic benefit will be required in settlement. an(J the am(wJnl of the settlement can be estimated reliably. Liabilities are recconised at the amount that the Company anticipates it will pay to settle the debt or the amcyjnt it has received as advanced payments for the goods or services il musl provide. Provisions are measured at the best estimale of Ihe amounls required to settle the obligation. Where the effect of the ts.rne value of money is material, the provision is based on the present value of those amounts. discounted al the pre-tsx dIunt rate that refl1$ the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost. 1.13 Penslons The charTlable company operates a defined contribulion pension scheme. Contributions payable to the charitable companls pension scheme are charged lo the Staternent of Financial Activities in the period to which they rdate. . ??
Do¢u8van Envelope10.. >)s485A&eAu1Y2.F6BDc1E87A FOLLICULAR LYMPHOMA FOUNDATION IA company Ilmlted by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Accounting policies (continu) 1.14Fund accounting General fvnds are unrestricted fvnds which are available for use al the discrotion of the Trustees in furtheran of the general objectives of the Company and which have Thjt been designated for other purposes. Restricted funds are funds which are to be used in accordartce wth specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The cosis of raising and administering such funds are charged against Ihe speafic fuThJ. The aim and use of each restrided fund is sel out in the rleS to the financial statements. Investment income, gains and losses are alIcted to the appropriate fund. Critical accounting estimates and area5 of judgment In preparing the finanual statements. Management are required lo make judgements. estimates and assurnplions that affect the reported amounts of assets, liabilits"es, income and expenditu. Estimates and underlwng assumplions are based on historical experience and other factors considered reasonable in the circumstances. and are reviewed on an ongoing basis. Actual results may differ from these eslirnales. The areas involving a higher degree of judgement. or where assumptions and estimates are significant to the financial slatemenls. are-. ReseaTch grant and programme commitments - iudgem8nt is applied in detemiining wheth8r a legal or constructsve obligation exists at Ihe year end. and the amounl al which any resulting liability is reeognised. The rrK)st significant such commitment is included withtn aceruals {note 14). Accft income - judgement and estimation are applied in detemining enlitlemenl to income receivable but not yel received at the yew end, and the amount at which it is re¢Tr3nised {nole 13}. Critic81 aecounting estimates and assumptions" The Company rnakes estimates and assumpknons CA)nceming the future. The resulting accounting estimates and assumption5 will. by definitson. seldom equal the related actual results. 944D44ar_tSxS2Sf-£5b64.W5Gj6*%8--.cft:-.?4
Oocu51gn Erwek¥e ID.. 305A85A8-6ADmAE4-8122.F68Dc1E8?A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 202S Income trom donallons Restricted Unrestricted funds funds 2025 2025 Total funds 2025 Donations Donated Services 958,784 1,340.774 110.698 2.299.558 110.698 Total 2025 958.784 1,451,472 2,410,256 Donaied services principally comprise legal and communications support. These a cOgnised as income al the fair value of the services received al the dale of donation. based on the estimated value to Ihe charity, with an equivalent amount recognisedas expendilure in the year. Restrictod Unrestricted funds funds 2024 2024 Total funds 2024 Donations 960,914 1,423,624 2,384,538 Investment income Unreslricted funds 2025 Total funds 2025 Deposil accounl interest 5.776 5,776 Unr•stricted funds 2024 Total funds 2024 Deposit account interest 7.241 7.241 l-.£wixi?.::' . ?
DooJsign Envelcpe ID.. 3Os485A&8A4l22.F6B0c1Es7A FOLLICULAR LYMPHOMA FOUNDATION {A company Ilmited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Other Income Unrestrlcted funds 2025 Total funds 2025 Total funds 2024 Recharge of shared costs wth FLF US 89.212 89212 Expenditure on rnislng funds Fundralslng trading expenses Unrestricted funds 2025 Tolal funds 2025 Fundraising fees Allocation of overheads Event costs Fundraising trading expenses- wage5 and salaries Fundraising trading expenses - Nl Fundraising trading expenses - pension costs 13.805 25.999 117,127 81,819 10.905 1.273 13.805 25.999 117.127 81.819 10.905 1.273 Tolal 2025 250.928 250.928 Unrestricted fund$ 2024 Total funds 2024 Fundraising fees Allocation of overheads Evenl costs FurKlraising trading expenses - wages and salaries Fundraising trading expenses- Nl Fundraising trading expenses- pension costs 1,431 28,912 107.893 76.104 9,678 612 1,431 28.912 107,893 76.104 9.678 612 Total 2024 224,630 224,630
DrU$*jn En¥eK)pe ID." 305A85A&8AD4-8AE4-8122-F6BLK1A8E87A FOLUCULAR LYMPHOMA FOUNDATION (A company Ilmlted by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Analysis of expenditure on charitable activities Summary by fund type Restricted Unrèstricted funds funds 2025 2025 Total 2025 Research and patient programmes (including wvemance cosls} Intercompany staff costs recharged Research and patient programme SUPFth costs 781,637 89.212 1.114.792 1.896.429 89.212 221.597 221.597 Totsl 2025 870.849 1.336.389 2.207.238 Reslri¢ted Unrestricted funds funds 2024 2024 Total 2024 Research and patient programmes (including govemance costs) Research and patient kyogramme SUPFMNI costs 1,369,078 670,662 152,147 2,039,740 152,147 Total 2024 1.369.078 822,809 2,191.887 Analysis of expenditure by activities Governance Direct rasèarch research and patient and patient programme programme support sts 2025 Total funds 2025 2025 Research and patient wogrammes Intercompany staff costs recharged Research and patient wogramme support costs 1.873.764 89.212 22.665 1.896,429 89.212 221.597 221.597 Total 2025 1,962,976 244,262 2.207.238 ?7
DoDJsign Envelopg ID.. 30sA85A8-8A4122-FeBDclA8É87A FOLLICULAR LYMPHOMA FOUNDATION IA Company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Analys1$ of expendlture by actlvltbes lcontinued) Governance Direct research and research patient and patient programme programme support Costs 2024 Tolal fvnds 2024 2024 Research and patient pro9rammes Research and patient programme support costs 2.020.780 18.960 152.147 2.039,740 152.147 Total 2024 2.020.780 171.107 2.191,887 Anatysis of support costs Research and patient programrne SllPPOrt costs 2025 Governance Costs 2025 Total funds 2025 Staff costs Marketing and Communications IT support cosis Travel and aeeommodation Bank eharges Database & CRM 132,403 50,027 25,900 1.521 2.539 21.761 1.144 77.023 3.340 1.795 29.¢4J4 1.203 167 132,403 50.027 25,900 1,521 2,539 21,761 1.144 77,023 3.340 1.795 29,004 1.203 167 Postage and stslionery Legal expenses Depreciation General and other Operating lease expenses Event $1S Staff training Stsff training and Recnjitsnent Re-allocation of ovetheads to direct programmes Foreign exchange losses Govemanee costs 23.838 1176,8091 26.741 23,838 (176.8091 26.741 22,665 22.665 Total 2025 22,665 221,597 244,262 *l
Dc¢usign Envgw ID: 3o5A85M-8AE4-8l22-F6BDcIA8EB7A FOLLICULAR LYMPHOIAA FOUNDATION IA company Ilmlted by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 Anatysis of expebKllture by activities (continued) Analysls of support costs Icontlnued Research and patient programme support costs 2024 Governance Costs 2024 Total funds 2024 Stsff costs Marketing and Communications Support and consultancy IT and support Travel and accommodation Bank charges Database & CRM Poslage and staliongry Administrative support Legal expenses Depreciation General and other Operating lease costs Staff training and Recruitrt*nt Re-allocation of overheads to direct prcgrammes Foreign exchange gain Govemance costs 182,444 42.190 28.760 16.229 470 2.422 18.064 395 13.857 3.845 2.015 2.797 24.344 46,777 1226,265) 16,197) 182,444 42,190 28.760 16,229 470 2.422 18,064 395 13.857 3.845 2.015 2.797 24.344 46,777 {226,2651 {6,1971 18,960 18.960 Tolal 2024 18.960 152.147 171,107 Where grant agreements provide for Ihe recovery of a ntribUtion towards the charitys central costs, thal funded element is recognised within the direcl costs of the relevant charitable adivity I'cost recovew). Central costs that are not recovered from funders are appoIoned across the charitys aclivilie5 and sh¢)wn as support costs. This ensures that costs met by funders are reported against the activity they support. while the residual cost of running the charity is transparenuy disdosed as support cost. Auditorfs remuneration 2025 2024 Fees payable to the Coryanys auditor for the audit of the Companrfs annual accounts 15.000 13.500
DoJn Envdope ID.. 30S485AWD4-eAE44122.F68OC1PAE87A FOLLICULAR LYMPHOMA FOUNDATION (A company lirnited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEMBER 2025 10. Staff $ts 2025 2024 Wages and salaries Social security eosts Contribution to defined contribution penSn schemes 680.871 92.684 7.504 612.299 74.976 6.680 781.059 693,955 The average numbgr of persi?n5 employed by the Company during the year was as follows.. 2025 No. 2024 No, Ernployees The average headcount distinguished between full time and part time staff are as follows: 2025 No. 2024 No. Full lime employees Part time employees The number of employees whose employee nerts (excluding employer pension costsy exceeded £60.000 was.. 2025 No. 2024 No. In the band £60,001 - £70,000 In the band £70.001 - £80.000 In the band £90,001 - £1M.OCwJ In the band £220,001- £230.LK)O In the band £240.IK)1- £250.CM)O Key management personnel comprise the members of the Senior Management Team, being those persons having authority and responsibility for planning, directing and controlling the activities of the charity. The lolal employee benefits of key management personnel were £478.17912024.. £412.3101.
D¢oJ*gn Envelope ID.. 305A85A&8AD4-8AE48122.F68DC1A8E87A FOLLICULAR LYMPHOMA FOUNDATION {A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 11. Trust8es' remunoration and gxp•nwJ During the year. no Trustee5 rKeived any remuneratM)n other benefits {2024 - £Nill. Donations from Trustees During the period. the lotsl aggregate amount of unrestricted donations from Trustees was £82.750 (2024.. £84,000). During the year ended 31 December 2025. no Trustee expenses have been incurred12024 - £Nill. 12. Tangible fixed assets Computer equlpment C05t or valuation At 1 January 2025 Additions 19,661 5,033 Al 31 December 2025 24.694 Depreciation Al 1 January 2025 Charge fof the year 12,280 3,340 Al 31 December 2025 15.620 Net book value At 31 December 2025 9.074 Al 31 De¢ernber 2024 7,381
Qrfu$ign Emiewe ID.. 30W5A84AD4-8AE414122fjBDClEe7A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2025 13. Debtors 2025 2024 Due within one year Trade debtors 409.330 634.557 200.631 12.043 Prepayments and acc[L1 income 1.043.887 212,674 14. Creditors: Amounts falling due within one year 2025 2024 Trade creditors Other tsxation and social securrty Olher Creditors Accruals and deferred income 126.348 25.362 2.220 601.243 18,262 22,558 1.937 743.356 755.173 786,113 The amount of deferred income induded in accnwls and deferred income is £nil (2024: £nill. . ?_3K3¥-: ??
DrKusNJn Envelope10.. 30SNASA&W-&4EU122.F68DC1P*E87A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 15. Statement of lunds Statement of funds . current year Balance at Tranyfers 31 between December funds 2025 Balance at 1 January 2025 Income Expenditure Unr¢strith funds Unrestn'ded funds 1,102,542 1.546.460 (1,587.3171 {40.276) 1.021.409 Balance at 31 December 2025 Balance at 1 January 2025 Transfers between funds Income Expenditure Reslrided funds Mark Foundation for Cancer Research- towards CURE FL research DKMS Stiftung Leben Spenden CURE FL 70.832 . 70.832 (50,532) 78.966 12.654 632.111 226.673 1621.855} 1165.894) {12.654) 40.276 139.745 Blood Cancer UK The Joyce & Noman Freed Charitable Trust 25,154 1,()0 {70,446) 54,708 137,074 958.784 1870.849) 40.276 265.285 Total of fund5 1.239.616 2.505.244 {2.458.166) 1.286.694 The Mark Foundation The funds are lo fund one Momentum Fellow. a posldocloral researcher conducting evidence-based laboralory, data, andlor medical science research al a non-profit institution. DKMS Stfftung Leben SpendeTr The funds are to fund feasibility and Phase 2a dinal trial evaluating the safety, feasibility. and preliminary effectiveness of huCART19IL18 therapy adfflinislered 7Mthout lymphodeplelion in patients with relapsed or refractory fdlicular lyn)phoma. CURE FL This programme brings together the BIOCKI Cancer United (BCU) formerly Leukemia & Lymphoma Society ILLS), the Fdlicular Lymphoma Foundatson {FLF), and the Institute for Follieular Lyfflphoma Innovation IIFLII to ioinUy fund high-quality. innovalive research thal advances the treatment of fDIIiGular -lymphoma.- Blood Cancer UK & The Joyce & Nonnan Fr¢od Charitable Tru$t Fundirsg lo idenlify Irealmenl pattems, dinrcal outcomes and risk clusters for newty diagnosed FL (FLI and de novo transfomied FL {tFL) undergoing treatL 4A4a-?yCl4fj=. . 72
DocusvJTr Envelope10.. 3O5A85A&E44l2268Dc1A8EB7A FOLLICULAR LYMPHOMA FOUNDATION IA company lirnited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 15. Statement of fvnds lconllnuedl Statement of funds - prior year Balance at Transfers 31 between December funds 2024 Balanco at 1 January 2024 Income Expenditure Unrestrlcted funds Unrestricted funds 1,103.336 1.430.865 (1.047.439) {384.220} 1.102.542 Balance at 31 Dacember 2024 Balance at 1 January 2024 Transfers between funds Income Expenditure Restricted funds Maurice Wohl Charitable Foundation - lowards Cure FL research Mark Foundati for Cancer Research - towards CURE FL research DKMS Stsftung Leben Spenden CURE FL 9).186 (173.9361 83,750 70.832 70,832 526.840 246.574 87.500 (577,3721 (468,0781 (74.8461 150.532) 78.966 12.654 300.470 Blood Cancer UK The Joyce & Nomian Freed Charitable Trust 100,000 (74,8461 2S.154 161.018 960,914 11,369,078) 384.220 137.074 Total of fuTrds 1.264.3S4 2.391.779 12.416.517} 1.239,616 rd?A
Docusw En¥ek)Fe10.. 3o5A85A844l22.F6BDCl4E8FA FOLUCULAR LYMPHOMA FOUNDATION (A company Ilmited by guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 16. Analysls of net assets between funds Analysis of net assets between funds - current year Restricted Unrestr•cted funds funds 2025 2025 Total funds 2025 Tangible fixed assels Currenl assets Creditors due within one year 9.074 1.767.508 {755.173) 9.074 2.032.793 {755.1731 265,285 Total 265.285 1.021.409 1.286.694 Analysis of net assets between funds - prior year Restricted Unre$tr•cted funds funds 2024 2024 Total funds 2024 Tangible fixed assets Current assets Creditors due within one ygar 7.381 7.381 1.881.274 2.018.348 1786.1131 1786,1131 137.074 Total 137.074 1,102.542 1.239,616 17. Reconclllation of net movement In funds lo net cash flow from operallng actlvilies 2025 2024 Net incomelexpendrture for the year las per Statement of Financial Activities) 47,078 124,738) Adjustrnents for: Depreciation eharges Interest received Ilncreaseydeerease in deblots Increasel{decrease) in creditors 3,340 15.7761 {831.2131 (30.9401 2,015 {7,2411 {128.8281 674,250 Net cash provid•d byl(used inl operating adivities {817,511 } 515,458 3Th.4 44A
DoSign Envelow 10.. 30s48&4&aAD4l2268DClA8Ea7A FOLLICULAR LYMPHOMA FOUNDATION (A company limited by guarantee) NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025 18. Analysls of cash and cash equivalents 2025 2024 Cash in hand 988.9 1.805,674 Total $h and cash equivalents 988.906 1.805.674 19. Analysis of changes in net debt At31 December 2025 January 2025 Cash flows Cash al bank and in hand 1,805,674 {1,9371 {816.768) 1283) 988,906 12.2201 Debt due Viithin 1 year 1.803,737 1817.0511 986,686 20. Members. liability The charitable company is limited by guarantee and has no share capital. In the event of the charitsble Company being wound-up. the liability in respect of the guarantee is limited to £10 per member of the charitable company during the time they are a rnember or within one year of ceasing to be a member, as slated in the Memorandum and Articles of Association. 21. Related party transactions The tharity is one of three affiliated organiSatKs - Ihe Follicular LphOrna Foundati(m {UKI, Follicular Lymphoma Foundalion US, and Follicular Lymphoma Foundation Israel Ltd {a public benefit company) - which share common founding Irusteeslmembers and. in part. common management. The charity holds an equal mgmbership interest. alongside six other members. in Follicular Lyinphoma Foundation Israel Ltd,. this interest carries no right to any distribution of profits or assets and is not considered to give the charity control. The charity has representa on the lrd of the Israeli entity. During Ihe year, the tharity recharged £89.212 of shared costs to Follicular Lymphoma Foundation US. recognised as other income in note S. Separalely. the Charity recognised £89,212 of staff costs incurred by Follieular Lymphoma Foundalion US in respect of research pro9ramme activity. included as charitable expenditure in note 7. Al the year end, £103,210 {2024= £nil) was receivable from Follicular Lymphoma Foundation US in respect of costs paid on rts behalf. The charity reiVed donations totalling £27,750 12024.. £nill from enkn.ties controtled by trustees. and £82.75012024.. £84,000) of unrestricted donations from trustees (see note 111. Trustee Lord Rithard Ifwfft Harrington is a director of Harvington Properties Ltd. Ouring the year, the charity purchased seThices from them totslling £31.671 {2024: £Nil). At the year end. the balance outstanding was £2.667.